EU Allows ‘Freezing’ & ‘Rolling Back’ Of Regulatory Timelines Due To COVID-19
Executive Summary
Guidance is now available to help drug companies that use the EU mutual recognition and decentralized procedures to handle regulatory processes during the COVID-19 crisis.
You may also be interested in...
Europe's COVID-19 Procedures ‘Must Not Be Delayed’
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.